ERR2598341
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 22
- umap1_2d
- -4.757572641
- umap2_2d
- -3.704030337
- umap1_3d
- 3.959500569
- umap2_3d
- 1.764063475
- umap3_3d
- -0.714861217
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.440
- INFLAMMATORY_RESPONSE+0.430
- COMPLEMENT+0.410
- INTERFERON_GAMMA_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- ALLOGRAFT_REJECTION+0.360
- KRAS_SIGNALING_UP+0.350
- COAGULATION+0.320
- INTERFERON_ALPHA_RESPONSE+0.310
- MYOGENESIS+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.670
- MYC_TARGETS_V1-0.560
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.480
- DNA_REPAIR-0.390
- WNT_BETA_CATENIN_SIGNALING-0.370
- CHOLESTEROL_HOMEOSTASIS-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.320
- MTORC1_SIGNALING-0.270
- MITOTIC_SPINDLE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598283 | fetal | fetal | 0.888 |
| 2 | ERR2598318 | fetal | fetal | 0.887 |
| 3 | SRR1797302 | — | cohortMD2 | 0.884 |
| 4 | d552ba81-1140-4ab6-a14c-659c07e494d0 | — | — | 0.883 |
| 5 | R232 | — | — | 0.878 |
| 6 | SRR5088928 | — | — | 0.875 |
| 7 | SRR5088910 | — | — | 0.873 |
| 8 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.869 |
| 9 | SRR5088905 | — | — | 0.867 |
| 10 | MDT-AP-0308 | Med | Medulloblastoma | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |